Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of NSC228155 in preparation of medicine for preventing and treating acute kidney injury

1. NSC228155, acute kidney injury technology, applied in the field of medicine, can solve the problems of lack of pharmacological activity of acute kidney injury, NSC228155 has not been found, etc.

Inactive Publication Date: 2020-07-03
JIANGSU CANCER HOSPITAL
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Aiming at the technical problems existing in the prior art, the present invention provides the use of NSC228155 in the preparation of drugs for the prevention and treatment of acute kidney injury, which solves the problem that the pharmacological activity of NSC228155 in acute kidney injury has not been found in the prior art. Lack of adequate and suitable drugs for the inhibition of renal tubular epithelial cell apoptosis and technical problems in the treatment of acute kidney injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of NSC228155 in preparation of medicine for preventing and treating acute kidney injury
  • Use of NSC228155 in preparation of medicine for preventing and treating acute kidney injury
  • Use of NSC228155 in preparation of medicine for preventing and treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 The therapeutic dose of NSC228155 has no toxic side effects on mice

[0046] 1 Experimental materials and methods

[0047] 1) Administration, feeding and sampling of mice

[0048] The C57BL / 6 species male mice used in the present invention (7 weeks old at the time of purchase, body weight 20-24g) were purchased from the Experimental Animal Center of Nanjing Medical University, raised in an SPF level barrier environment of the Experimental Animal Center of Nanjing Medical University, and the animals were free to eat , maintaining a circadian rhythm of 12 hours of light and 12 hours of darkness. Laboratory temperature: 20-25°C, humidity 50±5%. After 1 week of adaptive feeding, the mice were randomly divided into control group (n=20), NSC228155 group (n=20), cisplatin group (n=20), cisplatin+NSC228155 group (n=20), and the former Two groups can be used to evaluate the safety of NSC228155 on mice under this test system.

[0049] The present invention uses NSC2...

Embodiment 2

[0054] Example 2NSC228155 improves renal function and renal pathological damage in mouse cisplatin model

[0055] 1 Experimental materials

[0056] The C57BL / 6 species mouse and NSC228155 (purity ≥ 99%) used in the present invention are from the same source as in Example 1.

[0057] 2 Experimental methods

[0058] 2.1 Animal administration, modeling and sampling

[0059] The present invention uses NSC228155 (purity≥99%) purchased from Selleck Company. Dilute to 0.25 mg / ml with vehicle (5% DMSO, 35% PEG-300, 65% sterile saline) before administration. The dosage of mice in NSC228155 group and cisplatin+NSC228155 group was 2.5mg / kg, administered by intraperitoneal injection, and the administration volume was 0.1ml per 10g of body weight; mice in the control group cisplatin group were given the same volume of the above vehicle by intraperitoneal injection , administered once a day for a total of 5 days. On the day of the third administration, the cisplatin group and the cispl...

Embodiment 3

[0075] Example 3NSC228155 reduces cisplatin-induced apoptosis in renal cortex tissue

[0076] 1. Experimental materials and methods

[0077] The source and use of mice and NSC228155 were as described in Example 2. The establishment method of the mouse cisplatin model and the tissue samples were the same as those in Example 2.

[0078] 1) TUNEL staining

[0079] Vazyme's TUNEL staining kit was used to dewax and hydrate the paraffin-embedded tissue sections, and the fragmented DNA in the tissue samples was fluorescently labeled according to the instructions, and the images were read and photographed using a laser confocal microscope.

[0080] 2) Western blot and RT-PCR

[0081] 3) Statistical analysis

[0082] Histograms represent data using mean ± SEM. Analysis of variance (ANOVA) was used for comparison among multiple groups. P<0.05 was regarded as statistically significant.

[0083] 2. Experimental results

[0084] Since cisplatin has a direct killing effect on renal ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of NSC228155 in the preparation of a medicine for preventing and treating acute kidney injury, and particularly relates to application of NSC228155 for treating acute renalinjury by protecting renal tubular epithelial cells. NSC228155 can improve the renal function of a cis-platinum-induced acute kidney injury mouse model, improve the pathological changes of acute renal tubular injury, reduce the apoptosis of mouse kidney tissue, reduce the inflammatory response of kidney tissue, and improve the cis-platinum-induced mitochondrial function and oxidative stress status of the mouse renal cortex tissues and renal tubular epithelial cells and protect renal tubular epithelial cells.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to compound NSC228155 preventing and treating acute kidney injury by protecting renal tubular epithelial cells. Background technique [0002] Acute kidney injury (AKI) is a group of common clinical syndromes marked by a rapid decline in renal excretory function in a short period of time, and is characterized by high morbidity and mortality. Due to the lack of satisfactory treatment, AKI survivors are also prone to develop chronic kidney disease and even end-stage renal failure, which brings a heavy burden to the family and society. Globally, there are about 130 million AKI patients each year, about 85% of whom live in developing countries. In China, the total incidence of AKI is about 5 / 1000. About 2.9 million AKI patients were hospitalized in 2013, and the total cost was as high as 13 billion US dollars, accounting for 10% of the total national medical expenditure that year. AKI has compl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4439A61P13/12
CPCA61K31/4439A61P13/12
Inventor 周益琴张爱华
Owner JIANGSU CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com